Neurological damage: Promote neuroprotection and helps in recovery from neurological impairments
Table 2 presents adjusted estimates of clinical outcomes at key time points, which were all statistically significant, except for triglycerides and total, HDL, and LDL cholesterol concentrations (Supplemental File 3)
Observational studies show that people with diabetes using GLP1 therapies tend to have lower rates of dementia compared to those on other treatments
Immediate consultation is warranted if you develop: Rapid weight gain accompanied by swelling, shortness of breath, or decreased urine output (possible fluid retention or heart failure) Return of obesity-related complications such as uncontrolled blood pressure, worsening diabetes control (elevated blood glucose readings), or sleep apnea symptoms Severe increase in appetite that interferes with daily functioning or leads to binge eating episodes Psychological distress, depression, or anxiety related to weight changes Severe abdominal pain, especially radiating to the back, with or without vomiting (possible pancreatitis) Right upper quadrant abdominal pain, fever, or yellowing of skin/eyes (possible gallbladder disease) Gastrointestinal symptoms that persist after stopping Zepbound Follow-up schedule should be tailored to your individual risk factors and comorbidities
